Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach.
Damiana ScuteriLaura RombolàLuigi Antonio MorroneGiacinto BagettaShinobu SakuradaTsukasa SakuradaPaolo ToninMaria Tiziana CorasanitiPublished in: International journal of molecular sciences (2019)
Aging of the population makes of dementia a challenge for health systems worldwide. The cognitive disturbance is a serious but not the only issue in dementia; behavioral and psychological syndromes known as neuropsychiatric symptoms of dementia remarkably reduce the quality of life. The cluster of symptoms includes anxiety, depression, wandering, delusions, hallucinations, misidentifications, agitation and aggression. The pathophysiology of these symptoms implicates all the neurotransmitter systems, with a pivotal role for the glutamatergic neurotransmission. Imbalanced glutamatergic and GABAergic neurotransmissions, over-activation of the extrasynaptic N-methyl-D-aspartate (NMDA) receptors and alterations of the latter have been linked to the development of neuropsychiatric symptoms experienced by almost the entire demented population. Drugs with efficacy and safety for prevention or long term treatment of these disorders are not available yet. Aromatherapy provides the best evidence for positive outcomes in the control of agitation, the most resistant symptom. Demented patients often cannot verbalize pain, resulting in unrelieved symptoms and contributing to agitation. Bergamot essential oil provides extensive preclinical evidence of analgesic properties. Incidentally, the essential oil of bergamot induces anxyolitic-like effects devoid of sedation, typical of benzodiazepines, with a noteworthy advantage for demented patients. These data, together with the reported safety profile, form the rational basis for bergamot as a neurotherapeutic to be trialed for the control of behavioral and psychological symptoms of dementia.
Keyphrases
- essential oil
- sleep quality
- mild cognitive impairment
- end stage renal disease
- cognitive impairment
- ejection fraction
- chronic kidney disease
- chronic pain
- newly diagnosed
- depressive symptoms
- pain management
- neuropathic pain
- peritoneal dialysis
- stem cells
- adipose tissue
- metabolic syndrome
- patient reported outcomes
- physical activity
- mesenchymal stem cells
- machine learning
- patient reported
- spinal cord
- smoking cessation
- artificial intelligence